3rd generation LVV transduction system

An increasingly popular application of lentiviral vectors is the generation of CAR T cell therapies that enhance T cell antigen specificity and effector function in liquid cancers.

An increasingly popular application of LVV is in the generation of chimeric antigen receptor (CAR) T cell therapies, which change and enhance T cell antigen specificity and effector function in liquid cancers.

Lentiviral vectors are used in FDA-approved therapies for diseases including beta thalassemia and sickle cell anemia.

Several Food and Drug Administration (FDA)-approved LVV-derived therapies are used for treating diseases ranging from beta thalassemia to sickle cell anemia.

Current clinical 3rd generation LVV transduction systems use a 4-plasmid combination encoding critical structural and non-structural HIV-1 proteins while excluding HIV-1 major accessory genes.

Current clinical LVV delivery systems do not include HIV-1 major accessory genes; however, critical structural and non-structural HIV-1 proteins are encoded by the 4-plasmid combination that composes the 3rd generation LVV transduction systems.

Lentiviral vectors deliver transgenes and induce stable expression through genome integration.

LVVs are used to deliver and induce the stable expression of transgenes through genome integration.

Investigation of LVV integration has uncovered chimeric LVV-host transcripts and altered host transcript splicing patterns.

Investigation of LVV integration has uncovered the generation of chimeric LVV-host transcripts and altered host transcript splicing patterns.

LVVs integrate into host intronic and intergenic regions due to genomic accessibility, with no known bias toward specific target integration motifs.

LVVs integrate into host intronic and intergenic regions due to genomic accessibility, but there are no known biases toward specific target integration motifs.

LVV integrations driving oncogene expression could be a cause for malignancy development.

LVV integrations driving oncogene expression could be a cause for malignancy development.

Current clinical 3rd generation LVV transduction systems use a 4-plasmid combination encoding critical structural and non-structural HIV-1 proteins while excluding HIV-1 major accessory genes.

Current clinical LVV delivery systems do not include HIV-1 major accessory genes; however, critical structural and non-structural HIV-1 proteins are encoded by the 4-plasmid combination that composes the 3rd generation LVV transduction systems.

Source: Adaptation of lentiviral vectors for viral gene therapy and their impact on host cell biology.